Phase II Trial on Efficacy of mTOR Inhibitor RAD001 [everolimus] as Maintenance Therapy for Patients Above 60 Years in Mantle Cell Lymphoma After First and Second Line Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2012
At a glance
- Drugs Everolimus (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 08 Oct 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 20 Aug 2008 New trial record.